NCT05588453 - Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

November 15, 2025

Study Completion Date

November 15, 2025

Conditions

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Malignant Neoplasm in the BrainMetastatic MelanomaPathologic Stage IV Cutaneous Melanoma AJCC v8

Interventions

BIOLOGICAL

Natural Killer Cell Therapy

Given UD TGFbi NK cell IV

DRUG

Temozolomide

Given PO

Trial Locations (1)

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus